Local Viagra varieties - from Ranbaxy, Cadila and Torrent - finally arrive
After scrutinizing the applications for over 18 months to make andmarket an Indian version of Viagra (sildenafil), the Drug Controller General of India has finally sanctioned licenses to three domestic companies - Ranbaxy Laboratories, Zydus Cadila Healthcare and Torrent Pharmaceuticals - to sell a local variety of Pfizer's original erectile dysfunction drug, reports the Marketletter's New Delhi correspondent, Ajoy Sen.
The DCGI's approval will make sildenafil citrate available for the first time on the Indian market, which is home to over one billion people, with around 40 million males in the 40-70 age group who potentially suffer from various degrees of erectile dysfunction.
Likely price to be minimum $0.43 per 25mg pill
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze